Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter September 21, 2011

Long-term stability of endogenous B-type natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP) in frozen plasma samples

Thomas Mueller, Alfons Gegenhuber, Benjamin Dieplinger, Werner Poelz and Meinhard Haltmayer

Abstract

The aim of the present study was to assess the long-term stability of endogenous B-type natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP) in plasma samples stored at –20°C without addition of protease inhibitors (e.g., aprotinin). Stability of BNP and NT-proBNP was tested in 60 EDTA plasma samples with BNP values between 30 and 420 pg/ml. Initial BNP and NT-proBNP plasma concentrations were determined within four hours after blood collection using the AxSYM BNP and the Elecsys NT-proBNP assays. Subsequently, all samples were stored at –20°C and were thawed for the second BNP and NT-proBNP determination on the two instruments after one day, 30 days, 60 days, 90 days and 120 days, respectively. Mean recovery (i.e., residual immunoreactivity) of BNP and NT-proBNP expressed in percent of the initial value for the given time interval of storage was calculated. Mean recovery of BNP was less than 70% after one day of storage at –20°C and decreased to less than 50% after two to four months of storage (e.g., recovery of endogenous BNP after three months of storage at –20°C ranging from 0% to 71%). In contrast, mean recovery of NT-proBNP was generally greater than 90%, irrespective of the duration of storage at –20°C (e.g., recovery of endogenous NT-proBNP after three months of storage at –20°C ranging from 91% to 112%). In conclusion, the determination of endogenous BNP with the AxSYM assay using frozen plasma samples may not be valid under the conditions tested. In contrast, NT-proBNP as measured by the Elecsys assay may be stored at –20°C for at least four months without a relevant loss of the immunoreactive analyte.


Corresponding author: Meinhard Haltmayer, Department of Laboratory Medicine, Konventhospital Barmherzige Brueder, Seilerstaette 2, 4021 Linz, Austria. Phone: +43-732-7897-2201, Fax: +43-732-7897-2299, E-mail:

References

1 McCullough PA, Omland T, Maisel AS. B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Rev Cardiovasc Med 2003; 4:72–80.Search in Google Scholar

2 Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma amino terminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355:1126–30.10.1016/S0140-6736(00)02060-2Search in Google Scholar

3 Murdoch DR, McDonagh TA, Byrne J, Blue L, Farmer R, Morton JJ, Dargie HJ. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J 1999; 138:1126–32.10.1016/S0002-8703(99)70079-7Search in Google Scholar

4 Gegenhuber A, Mueller T, Firlinger F, Lenz K, Poelz W, Haltmayer M. Time course of B-type natriuretic peptide (BNP) and N-terminal proBNP changes in patients with decompensated heart failure. Clin Chem 2004; 50:454–6.10.1373/clinchem.2003.028712Search in Google Scholar

5 Buckley MG, Marcus NJ, Yacoub MH, Singer DR. Prolonged stability of brain natriuretic peptide: importance for non-invasive assessment of cardiac function in clinical practice. Clin Sci 1998; 95:235–9.10.1042/CS19980045Search in Google Scholar

6 Murdoch DR, Byrne J, Farmer R, Morton JJ. Disparity between studies of the stability of BNP in blood: comparison of endogenous and exogenous peptide. Heart 1999; 81:212–3.10.1136/hrt.81.2.212Search in Google Scholar

7 Shimizu H, Aono K, Masuta K, Asada H, Misaki A, Teraoka H. Stability of brain natriuretic peptide (BNP) in human blood samples. Clin Chim Acta 1999; 285:169–72.10.1016/S0009-8981(99)00112-6Search in Google Scholar

8 Downie PF, Talwar S, Squire IB, Davies JE, Barnett DB, Ng LL. Assessment of the stability of N-terminal pro-brain natriuretic peptide in vitro: implications for assessment of left ventricular dysfunction. Clin Sci 1999; 97:255–8.10.1042/CS19990084Search in Google Scholar

9 Buckley MG, Marcus NJ, Yacoub MH. Cardiac peptide stability, aprotinin and room temperature: importance for assessing cardiac function in clinical practice. Clin Sci 1999; 97:689–95.10.1042/CS19990194Search in Google Scholar

10 Gobinet-Georges A, Valli N, Filliatre H, Dubernet MF, Dedeystere O, Bordenave L. Stability of brain natriuretic peptide (BNP) in human whole blood and plasma. Clin Chem Lab Med 2000; 38:519–23.10.1515/CCLM.2000.076Search in Google Scholar

11 Evans MJ, Livesey JH, Ellis MJ, Yandle TG. Effect of anticoagulants and storage temperatures on stability of plasma and serum hormones. Clin Biochem 2001; 34:107–12.10.1016/S0009-9120(01)00196-5Search in Google Scholar

12 Yeo KT, Wu AH, Apple FS, Kroll MH, Christenson RH, Lewandrowski KB, Sedor FA, Butch AW. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 2003; 338:107–15.10.1016/j.cccn.2003.08.016Search in Google Scholar PubMed

13 National Committee for Clinical Laboratory Standards. Evaluation of precision performance of clinical chemistry devices; approved guideline. NCCLS document EP5-A. Wayne, PA: National Committee for Clinical Laboratory Standards, 1999.Search in Google Scholar

Received: 2004-2-23
Accepted: 2004-4-27
Published Online: 2011-9-21
Published in Print: 2004-8-1

© Walter de Gruyter

Scroll Up Arrow